Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Technology Council, IVD Provisions Get Go-Ahead By House/Senate Conferees

This article was originally published in The Gray Sheet

Executive Summary

A Medicare reform provision extending routine patient care coverage of breakthrough medical device trials would cost approximately $3.3 bil. less than the Congressional Budget Office originally scored, according to AdvaMed

You may also be interested in...



Diabetes, Wheelchair Firms Brace For DME Impact As Rx Bill Goes To Floor

Eleventh-hour efforts by Rep. David Hobson (R-Ohio) to craft language mitigating a reduction in payments for five DME product services appear to have fallen short, as the House and Senate prepare to begin floor debate on the Medicare bill

Diabetes, Wheelchair Firms Brace For DME Impact As Rx Bill Goes To Floor

Eleventh-hour efforts by Rep. David Hobson (R-Ohio) to craft language mitigating a reduction in payments for five DME product services appear to have fallen short, as the House and Senate prepare to begin floor debate on the Medicare bill

DME Competitive Bidding, New Tech Payments To Be Taken Up By Conferees

A provision establishing clinical trial coverage for Category A devices is part of a larger consensus reached by conferees on less controversial aspects of the "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1, S 1)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel